PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Up 5.9% – Here’s Why

Posted by George Bondi on Jul 10th, 2026

PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Get Free Report) shares rose 5.9% during trading on Friday . The company traded as high as $20.91 and last traded at $20.9250. Approximately 440,550 shares changed hands during trading, a decline of 72% from the average session volume of 1,567,738 shares. The stock had previously closed at $19.75.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PRCT. Leerink Partners downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $31.00 to $29.00 in a research report on Thursday, June 11th. Piper Sandler reaffirmed an “overweight” rating and set a $35.00 price target (up from $28.00) on shares of PROCEPT BioRobotics in a report on Thursday, April 30th. Evercore assumed coverage on shares of PROCEPT BioRobotics in a research note on Wednesday, June 24th. They set an “outperform” rating and a $30.00 price target on the stock. Wall Street Zen upgraded PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Truist Financial reiterated a “hold” rating and set a $25.00 price objective (down from $30.00) on shares of PROCEPT BioRobotics in a research note on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics has an average rating of “Hold” and an average price target of $37.27.

View Our Latest Report on PROCEPT BioRobotics

PROCEPT BioRobotics Trading Up 5.3%

The company has a quick ratio of 5.51, a current ratio of 6.73 and a debt-to-equity ratio of 0.15. The firm’s 50 day moving average is $24.77 and its two-hundred day moving average is $26.73. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -11.43 and a beta of 0.87.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). The company had revenue of $83.13 million for the quarter, compared to the consensus estimate of $80.52 million. PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period last year, the company posted ($0.45) earnings per share. Equities analysts anticipate that PROCEPT BioRobotics Corporation will post -1.53 EPS for the current year.

Institutional Investors Weigh In On PROCEPT BioRobotics

Several large investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc boosted its holdings in shares of PROCEPT BioRobotics by 994.5% during the second quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after acquiring an additional 1,084 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after purchasing an additional 746 shares during the last quarter. Center for Financial Planning Inc. acquired a new position in PROCEPT BioRobotics during the 4th quarter valued at about $40,000. Cache Advisors LLC bought a new position in PROCEPT BioRobotics in the 1st quarter worth about $42,000. Finally, Essential Partners LLC boosted its position in shares of PROCEPT BioRobotics by 7,071.4% during the first quarter. Essential Partners LLC now owns 2,008 shares of the company’s stock worth $50,000 after buying an additional 1,980 shares during the period. 89.46% of the stock is owned by institutional investors and hedge funds.

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.